Time course of fluorescent-labelled oligonucleotide accumulation in cells with the use of folate receptor-targeted cationic liposomes

INTRODUCTION. The use of cationic liposomes is a promising approach to the delivery of therapeutic nucleic acids to target cells because liposomes can protect nucleic acids from degradation by extracellular nucleases. However, to ensure selective delivery to the site of action, this approach needs modification, including liposome surface functionalisation with targeting ligands.
AIM. This study aimed to compare the time courses of the accumulation of a fluorescent-labelled oligonucleotide (FITC-ODN), which simulated a nucleic acid-based medicinal product, in cells with the use of folate receptor-targeted (F) and conventional (L) cationic liposomes.
MATERIALS AND METHODS. F- and L-liposomes were prepared using the polycationic amphiphile 2X3, the zwitterionic helper lipid DOPE, and the folate lipoconjugate F12. Physicochemical characterisation of the liposomes was performed using dynamic light scattering and transmission electron microscopy. Liposome–FITC-ODN complexes were formed at various nitrogen to phosphate (N/P) charge ratios. Flow cytometry, fluorescence microscopy, and confocal microscopy methods were used to study the accumulation of liposome–FITC-ODN complexes in human cervical carcinoma (KB-3-1) and human embryonic kidney (HEK 293) cells.
RESULTS. The prepared F- and L-liposomes were spherical particles with a diameter of 75–100 nm. The authors selected the optimal N/P ratio of 2/1 to obtain complexes of F- and L-liposomes with the FITC-ODN. This N/P ratio yielded homogeneous liposome–FITC-ODN complexes having a polydispersity index below 0.200 and a size of 112.4–125.1 nm. F-liposomes were 25% more efficient than L-liposomes in FITC-ODN delivery to KB-3-1 cells at 90, 120, and 240 minutes after transfection. In the first few minutes of cell transfection, fluorescence and confocal microscopy data on the distribution of liposome–FITC-ODN complexes showed that cationic liposome fluorescence signals colocalised with FITC-ODN signals. Later, FITC-ODN accumulation in the cytoplasm was observed.
CONCLUSIONS. Cationic liposomes demonstrated efficient FITC-ODN delivery into the cytoplasm of cancer cells. F-liposomes enhanced the percentage of transfected cells and improved FITC-ODN delivery compared with L-liposomes. The results obtained can be used in the further development of targeted medicinal products based on therapeutic nucleic acids and liposomes.

1. Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current state of human gene therapy: approved products and vectors. Pharmaceuticals (Basel. 2023;16(10):1416. https://doi.org/10.3390/ph16101416

2. Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022;2:24. https://doi.org/10.1038/s43586-022-00104-y

3. Zhang H, Vandesompele J, Braeckmans K, De Smedt SC, Remaut K. Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity. Chem Soc Rev. 2024;53(1):317–60. https://doi.org/10.1039/d3cs00194f

4. Zhang WW, Li L, Li D, Liu J, Li X, Li W, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29(2):160–79. https://doi.org/10.1089/hum.2017.218

5. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Appl Biosaf. 2020;25(1):7–18. https://doi.org/10.1177/1535676019899502

6. Shmendel EV, Puchkov PA, Maslov MA. Design of folatecontaining liposomal nucleic acid delivery systems for antitumor therapy. Pharmaceutics. 2023;15(5):1400. https://doi.org/10.3390/pharmaceutics15051400

7. Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416. https://doi.org/10.1016/j.addr.2022.114416

8. Iqbal S, Blenner M, Alexander-Bryant A, Larsen J. Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications. Biomacromolecules. 2020;21(4):1327–50. https://doi.org/10.1021/acs.biomac.9b01754

9. Rai DB, Pooja D, Kulhari H. 9 — Dendrimers in gene delivery. In: Pharmaceutical applications of dendrimers. Elsevier; 2019. P. 211–31. https://doi.org/10.1016/B978-0-12-814527-2.00009-3

10. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin Cancer Biol. 2021;69:226–37. https://doi.org/10.1016/j.semcancer.2019.10.020

11. Duan L, Xu L, Xu X, Qin Z, Zhou X, Xiao Y, et al. Exosomemediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13(3):1387–97. https://doi.org/10.1039/d0nr07622h

12. Luiz MT, Dutra JAP, Tofani LB, de Araújo JTC, Di Filippo LD, Marchetti JM, Chorilli M. Targeted liposomes: a nonviral gene delivery system for cancer therapy. Pharmaceutics. 2022;14(4):821. https://doi.org/10.3390/pharmaceutics14040821

13. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–9. https://doi.org/10.26355/eurrev_202102_24877

14. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrinand transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251–6. https://doi.org/10.1016/j.ejpb.2008.08.021

15. Wang B, Zhang J, Song F, Tian M, Shi B, Jiang H, et al. EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett. 2016;381(2):331–40. https://doi.org/10.1016/j.canlet.2016.08.006

16. Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–18. https://doi.org/10.3109/1061186X.2015.1052072

17. Kim SH, Kim JK, Lim SJ, Park JS, Lee MK, Kim CK. Folate-tethered emulsion for the target delivery of retinoids to cancer cells. Eur J Pharm Biopharm. 2008;68(3):618–25. https://doi.org/10.1016/j.ejpb.2007.08.010

18. Siwowska K, Schmid RM, Cohrs S, Schibli R, Müller C. Folate receptor-positive gynecological cancer cells: in vitro and in vivo characterization. Pharmaceuticals (Basel). 2017;10(3):72. https://doi.org/10.3390/ph10030072

19. Kalber TL, Kamaly N, So PW, Pugh JA, Bunch J, McLeod CW, et al. A low molecular weight folate receptor targeted contrast agent for magnetic resonance tumor imaging. Mol Imaging Biol. 2011;13(4):653–62. https://doi.org/10.1007/s11307-010-0400-3

20. Antony AC. The biological chemistry of folate receptors. Blood. 1992;79(11):2807–20. PMID: 1586732

21. Liang X, Luo M, Wei XW, Ma CC, Yang YH, Shao B, et al. A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy. Oncotarget. 2016;7(32):52207–17. https://doi.org/10.18632/oncotarget.10537

22. Kabilova TO, Shmendel EV, Gladkikh DV, Chernolovskaya EL, Markov OV, Morozova NG, et al. Targeted delivery of nucleic acids into xenograft tumors mediated by novel folate-equipped liposomes. Eur J Pharm Biopharm. 2018;123:59–70. https://doi.org/10.1016/j.ejpb.2017.11.010

23. Pierce JT, Cho SS, Nag S, Zeh R, Jeon J, Holt D, et al. Folate receptor overexpression in human and canine meningiomas — immunohistochemistry and case report of intraoperative molecular imaging. Neurosurgery. 2019;85(3):359–68. https://doi.org/10.1093/neuros/nyy356

24. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res. 2007;13(9):2557–67. https://doi.org/10.1158/1078-0432.CCR-06-1343

25. Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med. 2002;8(8):475–86. https://doi.org/10.1007/bf03402027

26. Shmendel EV, Kabilova TO, Morozova NG, Zenkova MA, Maslov MA. Effects of spacers within a series of novel folate-containing lipoconjugates on the targeted delivery of nucleic acids. J Drug Deliv Sci Technol. 2020;57:101609. https://doi.org/10.1016/j.jddst.2020.101609

27. Bishani A, Makarova DM, Shmendel EV, Maslov MA, Sen’kova AV, Savin IA, et al. Influence of the composition of cationic liposomes on the performance of cargo immunostimulatory RNA. Pharmaceutics. 2023;15(9):2184. https://doi.org/10.3390/pharmaceutics15092184

28. Petukhov IA, Maslov MA, Morozova NG, Serebrennikova GA. Synthesis of polycationic lipids based on cholesterol and spermine. Russ Chem Bull. 2010;59:260–8. https://doi.org/10.1007/s11172-010-0071-x

29. Luneva AS, Puchkov PA, Shmendel EV, Zenkova MA, Kuzevanova AY, Alimov AA, et al. Optimization of the technology for the preparation of cationic liposomes for the delivery of nucleic acids. Russ J Bioorg Chem. 2018;44:724–31. https://doi.org/10.1134/s1068162019010084

30. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815–23. https://doi.org/10.1038/nnano.2011.166

31. Mikheev AA, Shmendel EV, Nazarov GV, Maslov MA. Influence of liposome composition on plasmid DNA delivery to eukaryotic cells. Russ J Bioorg Chem. 2021;47:1034–42. https://doi.org/10.1134/S1068162021050319

32. Mornet E, Carmoy N, Lainé C, Lemiègre L, Le Gall T, Laurent I, et al. Folate-equipped nanolipoplexes mediated efficient gene transfer into human epithelial cells. Int J Mol Sci. 2013;14(1):1477–501. https://doi.org/10.3390/ijms14011477

33. Gorle S, Ariatti M, Singh M. Novel serum-tolerant lipoplexes target the folate receptor efficiently. Eur J Pharm Sci. 2014;59:83–93. https://doi.org/10.1016/j.ejps.2014.04.012